diabetes mellitus/tyrosine

FIELD OF THE INVENTION This invention is in the field of biological medicine and specifically relates to the preparation, pharmacological activities and application of twelve bromophenol compounds, including: (2'-bromo-6'-(dibromomethyl)-3',4'-dimethoxyphenyl)-(2,3-dibromo-4,5-dime-

FIELD OF THE INVENTION The present invention comprises small molecular weight, non-peptidic inhibitors of Protein Tyrosine Phosphatase 1 (PTP1) which are useful for the treatment and/or prevention of Non-Insulin Dependent Diabetes Mellitus (NIDDM). BACKGROUND OF THE INVENTION The mechanism of

The present invention comprises small molecular weight, non-peptidic inhibitors of Protein Tyrosine Phosphatase 1 (PTP1) which are useful for the treatment and/or prevention of Non-Insulin Dependent Diabetes Mellitus (NIDDM). BACKGROUND OF THE INVENTION The mechanism of insulin action depends

This application is the National Stage of Application No. PCT/EP2006/046543, filed on Dec. 6, 2006, which claims benefit under 35 U.S.C. .sctn.119(a-d) of U.S. Provisional Application No. 60/748,491, filed Dec. 8, 2005, the contents of which are incorporated herein by reference in their

1. INTRODUCTION The present invention relates to novel modalities for treatment of diabetes, and other diseases caused by dysfunctional signal transduction by receptor type tyrosine kinases, in particular the insulin receptor. The present invention further relates to methods for screening and

BACKGROUND OF THE INVENTION Detection of specific autoantigens in prediabetic individuals has been used as a predictive marker to identify, before clinical onset and significant .beta.-cell loss has occurred, those at greater risk of developing IDDM (Gorsuch et al., Lancet 2: 1363-65, 1981;

BACKGROUND OF THE INVENTION Insulin-dependent diabetes mellitus (IDDM) is a disease resulting from the autoimmune destruction of the insulin-producing .beta.-cells of the pancreas. Studies directed at identifying the autoantigen(s) responsible for .beta.-cell destruction have generated several

FIELD OF THE INVENTION This invention relates to the preparation of phosphatase inhibitors that act as phosphotyrosine mimetics. The invention particularly relates to compounds designed to inhibit protein-tyrosine phosphatase 1B, and for the treatment of diabetes. SUMMARY OF THE RELATED ART Protein

BACKGROUND OF THE INVENTION 1. Field of the Invention This invention relates to the preparation of phosphatase inhibitors that act as phosphotyrosine mimetics. The invention particularly relates to compounds designed to inhibit protein-tyrosine phosphatase 1B, and for the treatment of diabetes. 2.

1. INTRODUCTION The present invention relates to compounds capable of modulating and/or regulating the activity of phosphotyrosine phosphatases that regulate signal transduction. Specifically, the present invention relates to the use of such compounds for the treatment of diseases caused by

1. INTRODUCTION The present invention relates to compounds capable of modulating and/or regulating the activity of phosphotyrosine phosphatases that regulate signal transduction. Specifically, the present invention relates to the use of such compounds for the treatment of diseases caused by

1. INTRODUCTION 2. BACKGROUND OF THE INVENTION 2.1. Signal Transduction 2.2. Protein Tyrosine Kinases And Phosphatases 2.3. Abnormal Signal Transduction In Human Diseases 3. SUMMARY OF THE INVENTION 3.1. Definitions 4. BRIEF DESCRIPTION OF THE DRAWINGS 5. DETAILED DESCRIPTION OF THE INVENTION 5.1.

1. INTRODUCTION The present invention relates to compounds capable of modulating and/or regulating the activity of phosphotyrosine phosphatases that regulate signal transduction. Specifically, the present invention relates to the use of such compounds for the treatment of diseases caused by

1. INTRODUCTION The present invention relates to compounds capable of modulating and/or regulating the activity of phosphotyrosine phosphatases that regulate signal transduction. Specifically, the present invention relates to the use of such compounds for the treatment of diseases caused by

1. INTRODUCTION The present invention relates to compounds capable of modulating and/or regulating the activity of phosphotyrosine phosphatases that regulate signal transduction. Specifically, the present invention relates to the use of such compounds for the treatment of diseases caused by